PEAR1 Antibody (492621)

Human peripheral blood platelets were stained with Mouse Anti-Human PEAR1 Monoclonal Antibody (Catalog # MAB4527) followed by Allophycocyanin-conjugated Anti-Mouse IgG F(ab')2 Secondary Antibody (Catalog # F0101B) and Integrin alpha 2b/CD41 Fluorescein-conjugated Monoclonal Antibody. Quadrant markers were set based on isotype control antibody staining (Catalog # MAB002).

• Reactivity: Hu
• Applications: WB, Flow, CyTOF-ready
• Clone: 492621
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated
• Concentration: LYOPH

PEAR1 Antibody (492621) Summary

• Immunogen: Chinese hamster ovary cell line CHO-derived recombinant human PEAR1
  Leu21-Ser754
  Accession # Q5VY43
• Specificity: Detects human PEAR1 in direct ELISAs and Western blots. In Western blots, no cross-reactivity with recombinant human Tenascin R or recombinant mouse Tenascin C is observed.
• Source: N/A
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Mouse
• Gene: PEAR1
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • CyTOF-ready
  • Flow Cytometry 2.5 ug/10^6 cells
  • Western Blot 1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for PEAR1 Antibody (492621)

• Jedi
• PEAR1
• platelet endothelial aggregation receptor 1

Background

Platelet endothelial aggregation receptor 1 (PEAR1) is a 150 kDa type I transmembrane protein and member of the MEGF family of proteins (1). Human PEAR1 is synthesized as a 1037 amino acid (aa) precursor that contains a 20 aa signal sequence, a 735 aa extracellular domain (ECD), a 21 aa transmembrane region, and a 261 aa cytoplasmic region. The ECD consists of 15 EGF-like repeats that vary in length from 39 to 42 aa and contain a consensus sequence of CX_1-2GX₂GX_2-4CX₃CX_1-3CX_1-2GX_1-2CX₄GX₁CX₁CX₂GX₂GX₂C (1). The consensus repeat contains six conserved glycine residues and eight conserved cysteine residues, suggesting four disulfide-bonded cysteine pairs in each EGF repeat (1). Within the ECD, there are also five potential sites for N-linked glycosylation. The cytoplasmic region contains five potential Src homology 3-binding, proline-rich domains (1). Mature human PEAR1 is 84% aa identical to mature mouse PEAR1. PEAR1 is most highly expressed in platelets and endothelial cells (1). Functionally, PEAR1 is a receptor for a yet undetermined ligand that signals upon the formation of platelet‑platelet contacts induced both by platelet aggregations and by platelet centrifugation (1). The signaling enhances and stabilizes platelet thrombi (2). Upon aggregation, the surface-expressed protein is tyrosine-phosphorylated (1). This phosphorylation event is inhibited by the alpha _IIb beta ₃ antagonist eptifibatide, thus demonstrating that PEAR1 tyrosine phosphorylation is dependent on surface contacts between activated platelets (1). PEAR1 can be phosphorylated in an alpha _IIb beta ₃ integrin-dependent manner on tyrosine (Tyr925) and serine residues (Ser593 and Ser1029) and, potentially, at Tyr804, Tyr943, and Tyr979 (1). Inherited PEAR1 variations that alter expression or function of the platelet signaling molecule could modify agonist-induced aggregation in native platelets (2). In addition, a genetic variant in PEAR1 could be an important determinant of residual platelet function during aspirin treatment, because the COX1/thromboxane A2 pathway will be strongly inhibited by aspirin, and maximal aggregation will then be dependent on other secondary signaling pathways (2).

1. Nanda, N. et al. (2005) J. Biol. Chem. 280:24680.
2. Herrera-Galeano, J.E. et al. (2008) Arterioscler. Thromb. Vasc. Biol. 28:1484.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for PEAR1 Antibody (MAB4527)(1)

Publication using MAB4527

• JS Elenbaas, U Pudupakkam, KJ Ashworth, CJ Kang, V Patel, K Santana, IH Jung, PC Lee, KH Burks, JM Amrute, RP Mecham, CM Halabi, A Aliso, J Di Paola, NO Stitziel SVEP1 is an endogenous ligand for the orphan receptor PEAR1 Nature Communications, 2023-02-15;14(1):850. 2023-02-15 [PMID: 36792666] (Immunoprecipitation, Human)

Bioinformatics

• Gene Symbol: PEAR1
• Uniprot:
  • Q5VY43()